Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

Updates arrive automatically.

  • “e.l.f. Made to Stand Out”: e.l.f. Creates Handcrafted Holiday Campaign to Celebrate Self Expression, Individuality and Inclusivity
    PR·

    “e.l.f. Made to Stand Out”: e.l.f. Creates Handcrafted Holiday Campaign to Celebrate Self Expression, Individuality and Inclusivity

    Narrated by Alan Cumming, e.l.f. shares a holiday tale for everyone who was never made to fit the mold e.l.f. Brands, including e.l.f. Cosmetics, e.l.f. SKIN and e.l.f. Hair, part of e.l.f. Beauty (NYSE:ELF), is celebrating what makes every eye, lip and face one of a kind with "e.l.f. Made to Stand Out," the brand’s first-ever holiday campaign. Created entirely through handmade stop-motion animation, marking another eyes.lips.first for e.l.f., the campaign puts an unmistakable e.l.f. twist on nostalgic holiday storytelling to celebrate a simple truth: your difference is lowkey your gift. This press release features multimedia. View the full release here: https://www.businesswire.com/news

    $ELF
  • FTI Consulting Appoints Daniel Heywood as Senior Managing Director in Brisbane
    PR·

    FTI Consulting Appoints Daniel Heywood as Senior Managing Director in Brisbane

    FTI Consulting, Inc. (NYSE:FCN) today announced the appointment of Daniel Heywood as a Senior Managing Director in the Forensic and Litigation Consulting segment. He will help clients navigate complex commercial disputes, investigations and regulatory matters. Mr. Heywood, who is based in Brisbane, brings more than 17 years of forensic accounting experience. His areas of expertise include the quantification of economic loss, contract and post-acquisition disputes, class actions, professional negligence matters, insurance claims, insolvency litigation, forensic investigations, asset tracing and wage underpayment matters. "Daniel bring

    $FCN
  • Hotel101-Madrid Hits Record High of US$3.28 Million Monthly Recurring Revenues From October 1 to 31, 2026 With 97.41% Occupancy
    PR·

    Hotel101-Madrid Hits Record High of US$3.28 Million Monthly Recurring Revenues From October 1 to 31, 2026 With 97.41% Occupancy

    Hotel101-Madrid, the 680-room global prototype, has recorded its strongest monthly performance to date, providing further support for the Company’s asset-light condotel model as it advances its international expansion. Latest Photo of 680-room Hotel101-

    $HBNB
  • MicroVision Expands Collaboration with FieldAI Across Government and Industrial Autonomous Systems Programs
    PR·

    MicroVision Expands Collaboration with FieldAI Across Government and Industrial Autonomous Systems Programs

    MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, and automotive applications, today announced an expanded collaboration with FieldAI, a developer of autonomous robotic systems for government and industrial applications. MVIS)" data-mce-style="display: block; margin-left: auto; margin-right: auto;" height="338" src="https://ml.globenewswire.com/Resource/Download/1da378d3-deeb-4d93-9482-ea28611b4e49/picture1.png" style="display:block; margin-left:auto; margin-right:auto;" width="600" data-dpi="96" data-caption="MicroVision, Inc. (NASDAQ:MVIS)" data-filename="Picture1.png"> The c

    $MVIS
  • FF EAI Robotics Ecosystem (FFR) CEO YT Jia Shares Weekly Investor Update: Recaps FFR's Listing Closing and First Investor Day in New York; FFR Sold and Shipped 351 Robot Devices in October, Setting Another Monthly Record
    PR·

    FF EAI Robotics Ecosystem (FFR) CEO YT Jia Shares Weekly Investor Update: Recaps FFR's Listing Closing and First Investor Day in New York; FFR Sold and Shipped 351 Robot Devices in October, Setting Another Monthly Record

    FF EAI Robotics Ecosystem Inc. ("FFR") (NASDAQ:FFR), has officially listed on the U.S. stock market as the first pure-play Four-Core Full-Stack AI humanoid and bionic robotics company.FFR sold and shipped 351 devices in October, setting another monthly record. Since the Company began sales and deliveries at the end of February, cumulative sales and shipments have reached 1,168 units, topping 1,000 for the first time, and continuing to deliver at a positive gross margin.FFR and FFAI's New York regional operations are now up and running and are now officially recruiting business partners. The first phase covers New York, New Jersey, Massachusetts, southwestern Connecticut, and eastern Pennsylv

    $FFR
  • Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR Sold and Shipped 351 Robot Devices in October, Setting Another Monthly Record and Bringing Cumulative Sales and Shipments to 1,168 Units
    PR·

    Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR Sold and Shipped 351 Robot Devices in October, Setting Another Monthly Record and Bringing Cumulative Sales and Shipments to 1,168 Units

    FF EAI Robotics Ecosystem Inc. ("FFR") (NASDAQ:FFR), has officially listed on the U.S. stock market as the first pure-play Four-Core Full-Stack AI humanoid and bionic robotics company. FFR sold and shipped 351 devices in October, setting another monthly record. Since the Company began sales and deliveries at the end of February, cumulative sales and shipments have reached 1,168 units, topping 1,000 for the first time, and continuing to deliver at a positive gross margin. FFR and FFAI’s New York regional operations are now up and running and is now officially recruiting business partners. The first phase covers New York, New Jersey, Massachusetts, southwestern Connecticut, and eastern

    $FFAI$FFR
  • HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
    PR·

    HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan

    — Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant and clinically meaningful PFS and OS improvements — — Data selected for ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine —

    $HCM
  • Mesoblast Board Changes
    PR·

    Mesoblast Board Changes

    Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth. After 12 years of serving on the Board since 2014, Mr William Burns will retire from the Board at the Company’s 2026 Annual General Meeting. Ms Jane Bell AM will take over as Chair of the Nomination and Remuneration Committee, having been co-Chair with Mr Burns

    $MESO
  • Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
    PR·

    Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

    SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood flowThe system is designed to bring purposeful innovation to treating complex coronary calcium, with longer treatment lengths, more pulses and enhanced catheter deliverabilityApproval of the investigational system would further strengthen Abbott's comprehensive coronary devices portfolio, complementing its advanced imaging, lesion preparation and stent technologies

    $ABT
  • Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
    PR·

    Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

    Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ:AVR, ASX: AVR)) a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced 30-day clinical and hemodynamic outcomes for the Medium-size DurAVR® Transcatheter Heart Valve (THV) in twenty-two severe aortic stenosis patients with medium aortic annuli (aortic annulus area 492 ± 38 mm2). The DurAVR THV demonstrated single digit mean gradients, large effective orifice areas (EOAs), no moderate or severe paravalvular leaks and no valve related mortality,

    $AVR
  • TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
    PR·

    TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients

    Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions NAVIGATE-PCI shows Heartflow PCI Navigator drove modifications to stent length and lesion prep compared to angiography alone

    $HTFL
  • GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging
    PR·

    GE HealthCare debuts Allia Celeo, a ceiling-mounted interventional system designed for smooth procedural flow and AI-powered precision imaging

    Extra-wide-bore, cable-less ceiling gantry and real-time digital twin aim to keep cases moving, regardless of procedure type or patient size AI-powered precision imaging designed to automatically balance image quality and radiation dose in real time across 2D and 3D imaging Designed to work with the GE HealthCare clinical applications and compatible third-party technologies care teams already rely on, with the flexibility to support future solutions Predictive service support through OnWatch Predict, a deep learning-based technology designed to help minimize clinical operations disruptions for a reliable patient schedule GE HealthCare (NASDAQ:GEHC) today introduced Allia™ Celeo

    $GEHC
  • Affle to acquire Perion, to scale its CPCU business across Developed markets
    PR·

    Affle to acquire Perion, to scale its CPCU business across Developed markets

    Perion shareholders to receive US$ 11.70 per shareThe deal values Perion at an implied Equity value of ~US$ 420 millionCombined business strengthens AI-powered consumer conversions, expands global scale, delivers measurable ROI for advertisers and sustained long-term value creation

    $PERI
  • BMO Completes Acquisition of Euroz Hartleys Capital Markets Business, Strengthening its Leading Global Metals and Mining Franchise
    PR·

    BMO Completes Acquisition of Euroz Hartleys Capital Markets Business, Strengthening its Leading Global Metals and Mining Franchise

    BMO Financial Group (TSX:BMO) (NYSE:BMO) today announced the completion of its acquisition of the Australian capital markets business of Euroz Hartleys Group Limited (ASX: EZL), strengthening its leading global metals and mining franchise and expanding BMO Capital Markets' presence in Australia. The acquisition combines BMO's global investment banking and distribution capabilities with Euroz Hartleys' deep Australian expertise in equities research, institutional sales and trading, equity capital markets, mergers and acquisitions, and strategic advisory. The combined platform connects clients more directly with capital, investors and opportu

    $BMO
  • Venture Global Commences Commercial Operations of Phase One of Plaquemines LNG
    PR·

    Venture Global Commences Commercial Operations of Phase One of Plaquemines LNG

    COD declared just over 53 months from FID on Phase One First long-term sales and purchase agreement (SPA) cargo lifted by Shell On October 31, 2026, Venture Global (NYSE:VG) commenced commercial operations of the first phase of its second LNG export project – Plaquemines LNG – and the sale of low-cost, U.S. LNG to the first phase’s long-term customers. The commercial operations date (COD) for Phase 1 of Plaquemines LNG was reached in just over 53 months from the final investment decision on the project, making it among the fastest greenfield LNG projects ever completed. "Achieving commercial operations at the first phase of our second LNG project in 53 months is a testament to our

    $VG
  • Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
    PR·

    Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results

    Analyses presented at TCT highlight how patient selection, timely Impella support and consistent care protocols may help improve outcomes during and after complex heart procedures Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient’s heart during and after high-risk percutaneous coronary intervention (HRPCI). Real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and Europe show lower in-hospital cardiovascular mortal

    $JNJ
  • Perion Enters into Definitive Merger Agreement with Affle
    PR·

    Perion Enters into Definitive Merger Agreement with Affle

    All-cash price of $11.70 per share, a 34.5% premium to Perion’s closing share price on October 30, 2026 Perion ("Perion" or the "Company") (NASDAQ & TASE: PERI), an advanced technology leader solving for the complexities of digital advertising through AI-native execution infrastructure, and Affle 3iL Ltd., a subsidiary of Affle International Pte. Ltd. ("Affle"), a global technology company delivering AI-led solutions in mobile advertising, today announced that they entered into a definitive agreement under which Affle will acquire the Company in an all-cash transaction. Upon closing of the transaction, Perion will become a wholly-owned subsidiary of Affle, and will continue to operate und

    $PERI